Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Protein Analysis Reagents
  4. Bioactive Small Molecules
  5. Tocris Bioscience™ LY 2109761

Tocris Bioscience™ LY 2109761

Catalog No. 786450 Shop All R&D Systems Products
Click to view available options
Quantity:
10 mg
50 mg
This item is not returnable. View return policy
This item is not returnable. View return policy

Description

Selective TGF-β kinase inhibitor

LY 2109761 is a selective dual TGF-β receptor type I and II (TβRI/II) inhibitor (Ki values are 38 and 300 nM in a cell-free assay, respectively); it inhibits the kinase activity of both TGF-βRI and TGF-βRII. In vitro, it significantly inhibits the growth, motility, and invasiveness of L3.6pl/GLT pancreatic cancer cells and completely suppresses TGF-β-induced Smad2 phosphorylation. In vivo, LY 2109761, in combination with Gemcitabine, significantly reduces tumor volume and spontaneous abdominal metastases in a murine model of metastatic pancreatic cancer. LY 2109761 is orally bioavailable.

Specifications

Chemical Name or Material 4-[5,6-Dihydro-2-(2-pyridinyl)-4 H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]quinoline
CAS 700874-71-1
Quantity 50 mg
Target TGF-beta Receptor Inhibitors
Molecular Formula C26H27N5O2
Purity 0.98
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.